Colgate-Palmolive (CL) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
Colgate-Palmolive Company (CL) insider buying and selling: no purchases, 15 sales
125 Form 4 Table I transactions filed with the SEC by Colgate-Palmolive Company insiders between 2025-09-12 and 2026-10-02 (15-month history): 0 open-market purchases and 15 sales, plus 110 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $14.9M by Wallace Noel R. on 2026-08-05.
Colgate-Palmolive insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, Colgate-Palmolive insiders filed 15 sales worth $57.1M on the open market, and no purchases.
The biggest seller was Wallace Noel R. (Chairman, President & CEO): $34.0M in 3 sales, out of 8 different sellers.
The largest trade of the period was a sale of $14.9M on Aug 5, 2026, by Wallace Noel R. (Chairman, President & CEO). Form 4 on sec.gov (0001225208-26-007020).
None of the 15 sales carries the 10b5-1 plan flag on the Form 4 (sales scheduled months ahead).
The last three months show 4 sales, against 2 in the three before. The latest sale from Aug 24, 2026.
Against its sector (Consumer Defensive, 33 companies with an insider page on this site), over the same dates the median is 5 sales and 1 purchase on the open market. Colgate-Palmolive has more sales than 27 of the other 32, ranks 7 of 33 by net dollars sold, and 17 of the 33 have at least one purchase.
The 20 most important trades
With no open-market purchases, the table starts with CL's sales, largest first. The full history is in the tool above, already searched.
See all 125 CL trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2026-08-05 | 2026-08-06 | Wallace Noel R. | Chairman, President & CEO | $14.9M | S — Open-market sale2 Form 4 footnotesF2 Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan and the related tax withholding. F4 Weighted average price, as these shares were sold in multiple transactions at prices ranging from $92.00 to $92.93, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote. | SEC |
| 2026-08-04 | 2026-08-06 | Wallace Noel R. | Chairman, President & CEO | $14.8M | S — Open-market sale2 Form 4 footnotesF2 Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan and the related tax withholding. F3 Weighted average price, as these shares were sold in multiple transactions at prices ranging from $91.50 to $92.30, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote. | SEC |
| 2026-02-04 | 2026-02-06 | Sutula Stanley J Iii | Chief Financial Officer | $9.2M | S — Open-market sale2 Form 4 footnotesF2 Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan and the related tax withholding. F3 Weighted average price, as these shares were sold in multiple transactions at prices ranging from $93.97 to $94.53, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote. | SEC |
| 2026-02-04 | 2026-02-06 | Wallace Noel R. | Chairman, President & CEO | $4.3M | S — Open-market saleForm 4 footnoteF1 Weighted average price, as these shares were sold in multiple transactions at prices ranging from $93.74 to $94.17, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote. | SEC |
| 2026-02-11 | 2026-02-13 | Tsourapas Panagiotis | COO, Eur., APac, Afr Eur, Skin | $3.3M | S — Open-market sale2 Form 4 footnotesF2 Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan and the related tax withholding. F3 Weighted average price, as these shares were sold in multiple transactions at prices ranging from $94.50 to $94.78 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote. | SEC |
| 2026-02-04 | 2026-02-06 | Daniels Jennifer | CLO and Secretary | $2.1M | S — Open-market sale2 Form 4 footnotesF2 Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan and the related tax withholding. F3 Weighted average price, as these shares were sold in multiple transactions at prices ranging from $94.32 to $94.42, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote. | SEC |
| 2026-02-10 | 2026-02-12 | Hazlin John | Chief Growth Officer | $2.0M | S — Open-market sale2 Form 4 footnotesF2 Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan and the related tax withholding. F3 Weighted average price, as these shares were sold in multiple transactions at prices ranging from $94.19 to $94.30 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote. | SEC |
| 2026-02-05 | 2026-02-09 | Massey Sally | Chief Human Resources Officer | $1.5M | S — Open-market sale2 Form 4 footnotesF2 Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan and the related tax withholding. F3 Weighted average price, as these shares were sold in multiple transactions at prices ranging from $95.02 to $95.045 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote. | SEC |
| 2026-02-12 | 2026-02-13 | Tsourapas Panagiotis | COO, Eur., APac, Afr Eur, Skin | $1.5M | S — Open-market sale2 Form 4 footnotesF2 Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan and the related tax withholding. F4 Weighted average price, as these shares were sold in multiple transactions at prices ranging from $97.74 to $97.89 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote. | SEC |
| 2026-02-06 | 2026-02-10 | Malcolm Gregory | EVP and Controller | $1.2M | S — Open-market sale2 Form 4 footnotesF2 Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan and the related tax withholding. F3 Weighted average price, as these shares were sold in multiple transactions at prices ranging from $94.79 to $95.01 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote. | SEC |
| 2026-08-24 | 2026-08-26 | Tsourapas Panagiotis | COO, CD, EMEA, APac, Skin | $920k | S — Open-market sale Indirect holding, through: By Trust 2 Form 4 footnotesF1 Weighted average price, as these shares were sold in multiple transactions at prices ranging from $92.00 to $92.12, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 This amount includes 12,661 shares that were previously reported as directly beneficially owned. | SEC |
| 2026-05-07 | 2026-05-11 | Massey Sally | Chief People Officer | $752k | S — Open-market saleForm 4 footnoteF1 Weighted average price, as these shares were sold in multiple transactions at prices ranging from $87.36 to $87.53, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote. | SEC |
| 2026-08-06 | 2026-08-07 | Cahill John T | Director | $389k | S — Open-market sale2 Form 4 footnotesF2 Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan. F3 Weighted average price, as these shares were sold in multiple transactions at prices ranging from $93.3712 to $93.39, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote. | SEC |
| 2026-05-15 | 2026-05-18 | Malcolm Gregory | EVP and Controller | $203k | S — Open-market sale | SEC |
| 2025-11-21 | 2025-11-24 | Massey Sally | Chief Human Resources Officer | $100k | S — Open-market sale | SEC |
| 2026-08-05 | 2026-08-06 | Wallace Noel R. | Chairman, President & CEO | $11.6M | M — Option exerciseForm 4 footnoteF1 Exercise of stock options awarded under the issuer's incentive compensation plan. | SEC |
| 2026-08-04 | 2026-08-06 | Wallace Noel R. | Chairman, President & CEO | $11.6M | M — Option exerciseForm 4 footnoteF1 Exercise of stock options awarded under the issuer's incentive compensation plan. | SEC |
| 2026-02-04 | 2026-02-06 | Sutula Stanley J Iii | Chief Financial Officer | $8.0M | M — Option exerciseForm 4 footnoteF1 Exercise of stock options awarded under the issuer's incentive compensation plan. | SEC |
| 2026-02-23 | 2026-02-25 | Wallace Noel R. | Chairman, President & CEO | $6.6M | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF2 Withholding of shares for payment of tax liability incident to the vesting of PBRSUs under the issuer's incentive compensation plan. | SEC |
| 2026-02-11 | 2026-02-13 | Tsourapas Panagiotis | COO, Eur., APac, Afr Eur, Skin | $2.7M | M — Option exerciseForm 4 footnoteF1 Exercise of stock options awarded under the issuer's incentive compensation plan. | SEC |
The period balance: money in, money out
In the Form 4 filings submitted between Sep 12, 2025 and Oct 2, 2026 there is not one open-market purchase of Colgate-Palmolive Company: 15 sales worth $57.1M and zero dollars bought.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like Colgate-Palmolive Company's is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| F | Tax withholding (shares surrendered for taxes) | 52 | $18.4M |
| A | Grant or award | 48 | $343k |
| S | Open-market sale | 15 | $57.1M |
| M | Option exercise | 10 | $40.8M |
| Total | Everything filed in the period | 125 | $116.6M |
33 of the 125 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 19 distinct people or entities have filed Colgate-Palmolive Company transactions: none bought on the open market and 8 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
Of the 8 who sold on the open market (15 sales in all), the three biggest sellers account for $48.9M of the $57.1M: 86% of the money in three people.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Wallace Noel R. | Chairman, President & CEO | 15 | — | $34.0M (3) | 2026-09-18 |
| Sutula Stanley J Iii | Chief Financial Officer | 12 | — | $9.2M (1) | 2026-09-18 |
| Tsourapas Panagiotis | COO, CD, EMEA, APac, Skin | 15 | — | $5.7M (3) | 2026-09-18 |
| Massey Sally | Chief People Officer | 13 | — | $2.4M (3) | 2026-09-18 |
| Daniels Jennifer | CLO and Secretary | 8 | — | $2.1M (1) | 2026-02-25 |
| Hazlin John | Chief Growth Officer | 12 | — | $2.0M (1) | 2026-09-18 |
| Malcolm Gregory | EVP and Controller | 13 | — | $1.4M (2) | 2026-09-18 |
| Cahill John T | Director | 3 | — | $389k (1) | 2026-08-07 |
Shown here are the 8 who moved the most money, out of 19. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Feb 2026: 0 purchases and 8 sales, worth $25.1M. 11 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 0 | $0 |
| Sep 2025 | 0 | $0 | 0 | $0 |
| Oct 2025 | 0 | $0 | 0 | $0 |
| Nov 2025 | 0 | $0 | 1 | $100k |
| Dec 2025 | 0 | $0 | 0 | $0 |
| Jan 2026 | 0 | $0 | 0 | $0 |
| Feb 2026 | 0 | $0 | 8 | $25.1M |
| Mar 2026 | 0 | $0 | 0 | $0 |
| Apr 2026 | 0 | $0 | 0 | $0 |
| May 2026 | 0 | $0 | 2 | $955k |
| Jun 2026 | 0 | $0 | 0 | $0 |
| Jul 2026 | 0 | $0 | 0 | $0 |
| Aug 2026 | 0 | $0 | 4 | $31.0M |
| Sep 2026 | 0 | $0 | 0 | $0 |
| Oct 2026 | 0 | $0 | 0 | $0 |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
Colgate-Palmolive Company (CL) analysis page →
Other Consumer Defensive companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
None of the 15 sales in the table is flagged as scheduled (10b5-1 plan), the kind signed months ahead and executed automatically. Colgate-Palmolive has no open-market purchase (code P) in the history, the most common case in the S&P 500: insiders are already paid in stock. The latest filing is from Oct 2, 2026, and a Form 4 arrives up to two business days after the trade.
18 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.